EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY-NC 3.0

Pyrotinib Plus Trastuzumab as an Effective Later-Line Therapeutic Strategy for HER2-Positive Metastatic Colorectal Cancer: Results from a Phase II Study

Wenwei Yang iD, Jing Zhang, Guifu Wu, Wen Zhang, Aiping Zhou, Lin Yang, Yongkun Sun

Drug Design, Development and Therapy · 2025-11 · Volume 19 · 10269-10280

DOI: 10.2147/dddt.s558378 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Drug Design, Development and Therapy, 2025-11. Verfasst von Wenwei Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Scien…. Hauptthemen laut MEDLINE: Acrylamides, Aminoquinolines, Antineoplastic Combined Chemotherapy Protocols, Colorectal Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcrylamidesAminoquinolinesAntineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsErb-b2 Receptor Tyrosine KinasesTrastuzumabAdultAgedFemaleHumansMaleMiddle AgedDose-Response Relationship, Drug

Stichwörter der Autor:innen

HER2metastatic colorectal cancerpyrotinibtarget therapytrastuzumab

Substanzen

AcrylamidesAminoquinolinesErb-b2 Receptor Tyrosine KinasesTrastuzumabERBB2 protein, humanpyrotinib

Autor:innen und Institutionen

  • Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People's Republ…
  • Department of Medical Oncology, Beijing Chaoyang District Sanhuan Cancer Hospital, Beijing, 100122, People's Republic of China.

ORCID-Profile: Wenwei Yang

Zitieren

APA

Yang, W., Zhang, J., Wu, G., Zhang, W., Zhou, A., Yang, L., & Sun, Y. (2025). Pyrotinib Plus Trastuzumab as an Effective Later-Line Therapeutic Strategy for HER2-Positive Metastatic Colorectal Cancer: Results from a Phase II Study. Drug Design, Development and Therapy, Volume 19, 10269-10280. https://doi.org/10.2147/dddt.s558378

Vancouver

Yang W, Zhang J, Wu G, Zhang W, Zhou A, Yang L, et al. Pyrotinib Plus Trastuzumab as an Effective Later-Line Therapeutic Strategy for HER2-Positive Metastatic Colorectal Cancer: Results from a Phase II Study. Drug Design, Development and Therapy. 2025;Volume 19:10269-10280. doi:10.2147/dddt.s558378

BibTeX
@article{Yang2025,
  author = {Yang, Wenwei and Zhang, Jing and Wu, Guifu and Zhang, Wen and Zhou, Aiping and Yang, Lin and Sun, Yongkun},
  title = {Pyrotinib Plus Trastuzumab as an Effective Later-Line Therapeutic Strategy for HER2-Positive Metastatic Colorectal Cancer: Results from a Phase II Study},
  journal = {Drug Design, Development and Therapy},
  year = {2025},
  volume = {Volume 19},
  pages = {10269--10280},
  doi = {10.2147/dddt.s558378}
}
Kostenlos starten →